Diltiazem enhances the effects of triazolam by inhibiting its metabolism

Triazolam is metabolized by CYP3A4. Diltiazem is an inhibitor of this isozyme and interacts with midazolam, another substrate of this enzyme. Therefore the possible interaction between triazolam and diltiazem is worth investigation.

[1]  P. Neuvonen,et al.  Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice , 1995, Clinical pharmacology and therapeutics.

[2]  Y. Gaillard,et al.  Simultaneous screening and quantitation of alpidem, zolpidem, buspirone and benzodiazepines by dual-channel gas chromatography using electron-capture and nitrogen-phosphorus detection after solid-phase extraction. , 1993, Journal of chromatography.

[3]  L. Dubé,et al.  High-performance liquid chromatographic determination of diltiazem and four of its metabolites in plasma: evaluation of their stability. , 1988, Journal of chromatography.

[4]  C. Hunt,et al.  Effect of age and gender on the activity of human hepatic CYP3A. , 1992, Biochemical pharmacology.

[5]  S. Hasan,et al.  Triazolam in cirrhosis: Pharmacokinetics and pharmacodynamics , 1993, Clinical pharmacology and therapeutics.

[6]  N. Slater.  Therapeutic Drugs , 1992 .

[7]  T. Kronbach,et al.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.

[8]  D. Abernethy,et al.  Diltiazem treatment impairs hepatic drug oxidation: Studies of antipyrine , 1986, Clinical pharmacology and therapeutics.

[9]  J. Horn,et al.  Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy , 1986, Clinical pharmacology and therapeutics.

[10]  P. de Goede,et al.  Simultaneous determination of midazolam and its three hydroxy metabolites in human plasma by electron-capture gas chromatography without derivatization. , 1989, Journal of chromatography.

[11]  K. Renton.  Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. , 1985, Biochemical pharmacology.

[12]  M. Bottorff,et al.  Pharmacokinetic Interactions with Calcium Channel Antagonists (Part I) , 1991, Clinical pharmacokinetics.

[13]  R B Smith,et al.  A pharmacokinetic drug interaction between erythromycin and triazolam. , 1986, Journal of clinical psychopharmacology.

[14]  J. Backman,et al.  Dose of midazolam should be reduced during diltiazem and verapamil treatments. , 1994, British journal of clinical pharmacology.

[15]  U. Bondesson,et al.  Liquid-chromatographic quantification compared with gas-chromatographic-mass-spectrometric determination of verapamil and norverapamil in plasma. , 1988, Clinical chemistry.

[16]  R. Dahlqvist,et al.  Inhibition of desipramine 2‐hydroxylation by quinidine and quinine , 1988, Clinical pharmacology and therapeutics.

[17]  F. Guengerich,et al.  Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[18]  P. Neuvonen,et al.  Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole , 1994, Clinical pharmacology and therapeutics.

[19]  C. Bonfils,et al.  Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. , 1990, Drug metabolism and disposition: the biological fate of chemicals.